2012, ą 1




1. B.Maglakelidze, K.Gurielidze,  M.shvildadze*, Vinsent  Perreten*


J. Experimental and Clinical Medicine, 2012, 1, pp.11-19


Scientific-Industrial Company “Camelyn M”; Tbilisi, Georgia

*Laboratoire LASEVE, Universite du Que´bec a‘Chicoutimi, Canada


The effects of therapy with Camelyn-M1,  (active compound-“Camelyn M” obtained from special sort of honey in one of region of Georgia), were examined in 155 cancer patients, between 1950 and 2003,  on the III and IV stage of disease, mainly on the terminal stage of deeply lying tumors of internal organs. Active substance Camelyn-M is a mixture of different biologically active compounds: aldehydes, ketones, furfural, organic acids. Significant anticancer activity by Camelyn-M1 was observed in patients given intramuscularly 2 g of Camelyn-M1 2 times per day with Novocain. Number of patients with wearies cancer decease were as follows: 1.Carcinoma of prostate gland-20; 2.Carcinoma of uterine cervix-12; 3.Ovarian carcinoma-18; 4.Carcinoma of urinary bladder-20; 5.Renal tumor-10; 6.Colon cancer-30; 7. Fibrosarcoma-5; 8.Carcinoma of stomach-15, 9. Lung cancer-5;  10.Oesophagus cancer-10; 11.Larynx tumor-5; 12. Endothelioma-5. Camelyn-M1 displays a strong inhibiting action on the growth of certain forms of tumors in experiment, as well as in clinic, to the point of their full regression.

Two mechanisms by which preparation Camelyn-M1 exerts its effect were investigated. The first was immunomodulation. The mechanism of action involves the stimulation of three important cytokines: IL-2, IFNγ, and TNFα. The second was direct anticancer properties. In vitro experiments, Camelyn-M1 was found to be active against DLD-1 colon carcinoma and A-549 lung carcinoma cells, with IC50 values of  0.063 ± 0.006 µg/mL  and 0.078 ± 0.005 µg/mL , respectively. In vivo studies in mice showed that Camelyn-M1 possesses suppressive effects on tumour cell growth, 0.1 ml 35% solution of Camelyn-M1 caused full regression of tumor in maic.  It is concluded that the high anticancer effect of Camelyn-M1 and the absence of notable side-effects make Camelyn-M1 a promising therapeutic agent for the treatment of cancer patients. At the same time, the preparation stimulates growth and reproduction of young connective tissues.


2. Benedikte Maglakelidze1, Guguli Abashidze1,  Inga Dadeshidze2,

Vakxtang Mshvildadze3, Andre Pichete3,   Vincent Perreten4  Shota Tsanava5,  Nata Shubladze6,  Koba Gurielidze1




J. Experimental and Clinical Medicine, 2012, 1, pp.19-23


1. Scientific-Pharmaceutical Company “Camelyn”, Tbilisi, Georgia;

2. Kutateladze Institute of Pharmacochemistry, Tbilisi, Georgia;

3. Laboratoire LASEVE, Universite du Que´bec a‘Chicoutimi, Canada;

4. Institute of Veterinary Bacteriology,University of Berne, Switzerland;

5. National Center for Disease Control & Medical Statistics, Tbilisi, Georgia;

6. National Center for Tuberculosis and Lung Diseases,  Tbilisi, Georgia.


The minimum inhibitory concentration (MIC) of Camelyn-M active compound obtained from special sort of honey in one of region of Georgia, was determined both by agar and broth dilution methods against some of strains of bacteria and fungy.  The antibacterial action of Camelyn  was further tested in animal models. Camelyn  was seen to possess powerful inhibitory action (0,012-0,150 µg/mL ) against most test bacteria in in vitro studies. In vivo studies showed that the drug offered significant protection (p<0.001) to mice challenged with a virulent bacterium.


3. Inga Dadeshidze1, Vakxtang Mshvildadze2, Andre Pichete2,

Koba Gurielidze3

In Vitro Antifungal Activities of Camelyn-M

J. Experimental and Clinical Medicine, 2012, 1, pp.23-27


1.Kutateladze Institute of Pharmacochemistry, Tbilisi, Georgia.

2.Laboratoire LASEVE, Universite´ du Que´bec a‘Chicoutimi, Canada

3.Scientific-Pharmaceutical Company “Camelyn” Tbilisi, Georgia.


Candida species are an important cause of opportunistic infection in the oral cavity of immunocompromised patients, especially HIV infected patients. The activities of Camelyn-M, a mixture of  natural compounds isolated from special sort of honey, distributed in one of region of Georgia, were evaluated in vitro. Camelyn exhibited potent in vitro activities against fluconazole-resistant strains of Candida albicans , Candida glabrata, Candida tropicalis, Candida parapsilosis and Candida krusei, with MICs at which 90% of isolates were inhibited of 0.012 µg/ml, respectively.




Local application of “Camelin” in complex with standard anti-TB treatment of tuberculous pleural empyema in drug-resistant cases

J. Experimental and Clinical Medicine, 2012, 1, pp.27-31


Investigation of local applications of Camelin as endopleural applications in patients with MDR-tuberculous pleural empyema (n=20) effectiveness in complex with standard anti-TB treatment showed that positive effect (empyema liquidation, cavity and exudate decreasing, elimination of secondary infection) is reliably higher with Camelin in comparison with standard TB pleural empyema treatment alone (retrospective analysis, n=20): RR-2; 955 CI=1,12-3,57; p value=0,009. Also, it was noted improvement of TB-patients’ immune status as a result of main TB process positive dynamics.



Treatment for pregnant and postpartum women with hemorrhoidal crises using Camelyn

J. Experimental and Clinical Medicine, 2012, 1, pp.31-34


Using  of medication  “Camelyn”  in both form  of ointment  and the rectal  suppositories, is an effective treatment for pregnant and postpartum women, with hemorrhoidal crises. Speed  of effective action and good tolerability  medication can be recommended for widespread use in obstetric practice. treatment for pregnant and postpartum women, with hemorrhoidal crises



6. I. kachkachishvili, m.baqradze, b. korsantia

Camelinotherapy in treatment of periodontitis using the method of electrophoresis

J. Experimental and Clinical Medicine, 2012, 1, pp.34-39


Ltd “Mitra” Dental clinic, Tbilisi State Medical University doctorant;

Shota Rustaveli State University, Batumi Georgia

TSMU Medical Biotechnology Institute, Georgia;


The original therapeutic-prophylactic agent of domestic manufacture – “Camelin” has been used for treating parodontosis. 25 patients have been observed, with acute forms of parodontosis, undergoing the traditional treatment in line with electrophoresis with 3% solution of “Camelin M1”. In comparison with the traditional treatment the results have shown the more rapid positive dynamics (reducing of blooding and inflammatory signs, disappearing of ache, itch symptoms, foul-smelling and taste from mouth cavity). Furthermore, the terms of remission have been increased. The immunomodulatory effect of the medicine, neutralization of immunopathological condition and the clear advantage in comparison with a traditional treatment have been approved once more.




Immunological aspects of burn patients in the treatment of Camelyn

J. Experimental and Clinical Medicine, 2012, 1, pp.39-42


TSMU Institute of Medical Biotechnology;

Center of Thermal Injures and Plastic Surgery, Tbilisi, Georgia


In the present study made   an analysis of immune homeostasis in patients with thermal injury and burn disease. The results of examination of patients with thermal injury showed significant changes in the immune system, affecting all its factors. The most significant was depressed T-immunity (and especially - interferon) at the stage of  burn shock. Camelyn the first time we have used for burns as an adjuvant means significantly increased the effectiveness of traditional treatment of burn disease and promotes reliable immunorehabilitation of patients.





J. Experimental and Clinical Medicine, 2012, 1, pp.42-44


Clinical Training Center of  Family Medicine Ltd, Tbilisi, Georgia


When using the Camelyn for the treatment of stomatitis and gingivitis the expressed clinical effect is received. About 2-3 days improvement of subjective signs, and objectively - acceleration of epithelisation of tissue was observed. No adverse effects were detected. The recommendation on wide application of spray in a dental practice is given.



9. N.Saakashvili, T.Chilingarishvili, K.Maglakelidze


J. Experimental and Clinical Medicine, 2012, 1, pp.44-47


Tbilisi Balneology Resort –SPA National Scientific/Practical Center Of Health

And Medical Rehabilitation, Georgia


Camelyn is biology active preparate, produced by Georgian famous surgery Benediqt Maglakelidze in the middle of XX century,from special, ecology clean, Kolkhis honey. After a lot of clinical and experimental trials, was determined, that Camelyn has immunomodulate, antioxidant and antiinflamatory action.

As osteoarthritis and osteochondrosis are most common medical problems in the world. It’s the number one cause of disability in America. Nearly 40 million Americans have some forms of  arthritis. Althought acure has yet to be found, effective treatments and other strategies are readily available. That’s why, we decided to consider the need of usage of the ultraphonophoresis of Camelyn-M3 (20 patients) and electrophoresis of Camelyn-M” (20 patients) for treatment of some forms of osteoarthritis and osteochondrosis.

As we have managed high therapeutic effect and improving of the quality of life in both groups, we recommend to use these new effective methods widly in clinical, physical medicine and rehabilitation.